| FDA approves targeted Pfizer drug for patients with recurring kidney cancer - Washington Post |
|
|
Washington Post The Food and Drug Administration approved the company's drug Inlyta as a secondary option for patients with renal cell carcinoma that hasn't responded to previous drug treatments. Renal cell carcinoma is the most common form of kidney cancer, ... FDA approves axitinib for renal cell carcinoma HemOncToday U.S. Food And Drug Administration Approves Pfizer's INLYTA(R) (axitinib) For |